Biliary tract carcinoma (BTC) is an extremely malignant tumor, but available treatment options are limited. Despite of needs for novel therapies, few BTC-related resources are currently available for evaluation of candidate drugs. To address this issue, we have recently established 13 cell lines from surgical specimens from Japanese BTC patients. In the present study, we evaluated four new molecular targeting agents using our BTC cell-based assay panel with 17 BTC cell lines. PI3K/ mTOR dual inhibitor LY3023414 showed activity at submicromolar concentration ranges against 13 of the 17 cell lines tested, including the ones with gemcitabine insensitivity. In conclusion, we demonstrated that in vitro study with the BTC cell line panel would be an efficient approach to screen for novel therapeutic strategies. Although this is preliminary result and further investigations are required for confirmation, PI3K/mTOR inhibitor might be a potential target for BTC drug development.
Introduction
Biliary tract carcinoma (BTC) is an extremely malignant tumor. The incidence and mortality rates of BTC are rising and are particularly high in Asian countries including Japan. Although surgical resection is the only curative treatment, most cases are first diagnosed at advanced and inoperable stages. For such patients, systemic chemotherapy is a standard treatment. Although gemcitabine plus cisplatin has become the standard regimen based on ABC-02 trial (1) , newer standard has not been established since then and the prognosis of BTC patients with advanced disease still remains dismal. Therefore, innovation in systemic chemotherapy is needed.
Despite of such needs for novel therapies, there are few BTCrelated resources currently available for evaluation of candidate drugs. To address this issue, we have recently established 13 new cell lines from surgical specimens from Japanese BTC patients at the National Cancer Center Hospital, Japan (2, 3; Table 1 ). While we established the cell lines, we also collected clinicopathological information of the corresponding patients, as well as genomic, epigenetic and proteomic information of the cell lines. With a panel of these well-characterized new BTC cell lines, we can now provide a comprehensive in vitro assay system to evaluate anti-proliferative actions of candidate drugs for BTC treatment. Actually, our cell lines have been successfully used to evaluate and identify new therapeutic strategy (4), which led to a clinical trial (UMIN000023014).
In the present study, we evaluated four new molecular targeting agents using our BTC cell-based assay system. The molecular targets of these four agents are reported to be possibly relevant to etiology of BTC (4) (5) (6) . For example, PIK3CA and FGFR have been identified as a potential driver oncogene for BTC (5) . Because these agents are already at various stages in clinical development for human patients, such preclinical evaluation could open up a way to quick expansion of clinical application of the agents for BTC.
Materials and methods

Cell lines and therapeutic agents
We previously established 13 cholangiocarcinoma cell lines derived from Japanese patients (NCC-CC1, NCC-CC3-1, NCC-CC3-2, NCC-CC4-1, NCC-CC4-2, NCC-CC4-3 (NCC-CC5), NCC-CC6-1, NCC-CC6-2, NCC-BD1, NCC-BD2, NCC-BD3, NCC-BD4-1, NCC-BD4-2; Table 1 ). Four human cholangiocarcinoma cell lines derived from Japanese patients (TKKK, OZ, TGBC24TKB and HuCCT1) were purchased from RIKEN Bio Resource Center (Tsukuba, Japan) or from the Japanese Collection of Research Bioresources (Osaka, Japan).
FGFR inhibitor LY2874455 (7), GSK3β inhibitor LY2090314 (8), PI3K/mTOR dual inhibitor LY3023414 (9) and VEGFR2 antibody ramucirumab (10) were provided by Eli Lilly (Indianapolis, IN, USA). Gemcitabine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Small molecule inhibitors were dissolved in DMSO (SigmaAldrich) to prepare 10 mM stock solution. These stock solution and ramucirumab were diluted with culture medium for cell-based assay.
Cell culture
The 13 cell lines we established and HuCCT-1 were grown in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% FBS and 1% penicillin/streptomycin (PS) and passaged. Cell lines OZ, TKKK and TGBC24TKB were grown in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich) supplemented with 10% FBS and 1% PS. The cell culture was maintained at 37°C in 5% CO 2 .
MTS assay
Cells were seeded in 96-well plates at 3000 cells per well. After 24 h under cultivation, cells were treated with gemcitabine (concentration range, 0.001-100 μmol/l) or four other drugs (concentration range, 0.00001-10 μmol/l). Each treatment was performed in triplicate of wells. After the treatment with test drugs for 72 h, the cell viability was determined using CellTiter-96 (Promega, Madison, WI, USA). Cell viability for each treatment was normalized against untreated cells. The plate was scanned at 490 nm in a 96-well plate reader.
Results
Using the 13 cell lines established from BTC patients and four commercially available cell lines, we evaluated the inhibitory effect of various types of drugs on their proliferation. As shown in Table 1 , gemcitabine showed anti-proliferative effect in 11 cell lines with IC50 value of less than 10 μM. Ramucirumab and LY2874455 did not inhibit the proliferation of these cell lines more than 50% at the tested concentrations, except for NCC-BD2 treated with LY2874455. LY2090314 showed inhibitory effects in some cell lines with IC50 values of second digit nanomolar range. LY3023414 showed inhibitory effect at submicromolar range in 13 cell lines. Notably, the LY3023414 inhibited growth of the cell lines NCC-BD2, NCC-BD3 and OZ, which are insensitive to gemcitabine (Table 1, Fig. 1 ). Inhibition of proliferation by LY3023414 was almost complete at 1 μM in cell lines NCC-BD2 and NCC-BD3.
Discussion
Although the need for developing novel therapeutic strategies is increasing, there are few BTC cell lines and xenograft models available for preclinical studies. We previously established 28 xenograft models and 13 new BTC cell lines from patient samples (2, 3). Most of our cell lines were found to be sensitive to gemcitabine, which is currently the first choice of treatment, suggesting that we have successfully established a preclinical study system and appropriate parameters for new drug screening.
In the present study, using 17 BTC cell lines, we evaluated antiproliferation activities of four new drugs with different mechanism of actions as well as gemcitabine. Based on their activity, these drugs were categorized into three groups: (1) drugs showing activity in most of cell lines, (2) drugs not showing activity in most of cell lines, (3) drugs not categorized into (1) and (2) . As reported previously (3), gemcitabine showed anti-proliferation activity in most of cell lines and was categorized as the group 1. In addition, LY3023414, a dual inhibitor for PI3K and mTOR, also showed activity in most of cell lines. However, anti-VEGFR-2 antibody ramucirumab and FGFR inhibitor LY2874455 did not show significant anti-proliferative activity for most of the cell lines tested, suggesting the signal pathways with VEGFR-2 and FGFR might not directly contribute to the proliferation of these cell lines in vitro. Lack of efficacy with ramucirumab may be due to the fact that this was in vitro assay with cultured tumor cells only, in contract to the previous report that demonstrated efficacy of axitinib in xenograft model, at least partly through its anti-angiogenic activity (4).
Anti-proliferative activities of GSK-3 inhibitor were observed in some of cell lines. Since the reasons for the observed variation of their sensitivities are unknown, further studies including genetic characterization would be necessary.
LY3023414 is a potent and selective inhibitor of Class I PI3K isoforms, mTORC1/2 and DNA-PK (9). In vitro, inhibition of PI3K/ AKT/mTOR signaling by LY3023414 caused G1 cell-cycle arrest and resulted in broad anti-proliferative activity in cancer cell panel screen (9) . In the current study, we found that even in the cell lines insensitive to gemcitabine, LY3023414 showed anti-proliferative activity and it inhibited the proliferation nearly completely at 1 μM (Fig. 1) . Mechanisms of the insensitivity to LY3023414 may involve difference of several signal cascade systems such as MAGEH1, as we previously reported (2) . The anti-proliferative activity of LY3023414 in the cell lines insensitive to gemcitabine we found in this study is promising for further characterization of LY3023414 in vitro and in vivo. For example, it is known that PIK3CA mutation induces constitutively active form of PI3K (11) and contributes to cell proliferation. According to our preliminary genetic examination of the cell lines, we could not find known gain-of-function nor loss-of function mutations in the components of PI3K-mTOR pathway (PI3K, PTEN, Akt, mTOR) (data not shown).
The anti-proliferative activity of LY3023414 was observed at approximately same concentration range in BTC cell lines (this study) as in cell lines of other tumor types (9) . Therefore, the mechanism of LY3023414's action in BTC cell lines might be similar to that in others (i.e. inhibition of PI3K/AKT/mTOR signaling). This is the first study to show the potential involvement of this pathway in the cell lines derived from BTC patients. The preliminary findings in this study indicate that further preclinical and clinical evaluation of LY3023414 for BTC is warranted. Especially, combination of LY3023414 with gemcitabine in the proliferation assay and/or in xenograft model would be worthy to investigate. In the future, efficacy of LY3023414 in BTC patients who failed to respond with standard therapy with gemcitabine would also be important. With a combination of gemcitabine and cisplatin, LY3023414 showed additive and/or synergistic effect on proliferation of several types of tumor cells, and in vivo efficacy of LY3023414 was reported in cancer patient-derived xenograft models (9, 12) . In the firstin-human study for LY3023414, durable partial response according to RECIST was observed in an endometrial cancer patient harboring PIK3R1 and PTEN mutations and 22 additional patients (47%) had stable disease as their best response (13) . Tumor-specific expansion cohorts of the Phase 1 trial are ongoing for mesothelioma, breast cancer, indolent Non-Hodgkin Lymphoma and squamous non-small cell lung cancer (sqNSCLC) (NCT01655225), and Phase 2 trials for castration resistant prostate cancer (NCT02407054), sqNSCLC (NCT02443337) and endometrial cancer (NCT02549989) are also ongoing. Based on the findings of this study as well as the clinical responses in Phase 1 study above, clinical study of LY3023414 in BTC patients would be encouraged.
In conclusion, we demonstrated that preclinical model using the BTC cell lines would be a new approach to screen various types of drugs in vitro. Our preliminary results indicates that PI3K/mTOR inhibitor might be a potential new agent for BTC drug development if validated by further research activity such as mechanistic studies and in vivo studies.
